Depletion of lipid stores is commonly found in cancer patients and may account for the largest part of the weight loss seen in cancer-bearing states (McAndrew, 1986) . The effect appears unrelated to nutrient intake, since pair-fed animals do not lose as much fat as tumour-bearing animals (Lundholm et al., 1981) , and loss of body fat can occur in the absence of anorexia (Beck & Tisdale, 1987 ). An increased mobilisation of host adipose tissue may begin early in the development of the tumour (Beck & Tisdale, 1987; Kralovic et al., 1977) , and in tumours which produce cachexia is directly related to the tumour burden (Hollander et al., 1986) .
The mechanism for the increased mobilisation of host lipids in the tumour-bearing state is unknown, but may be related to the production of a lipolytic factor by the tumour cells. Loss of body fat can be produced by the injection of a non-viable preparation of Krebs-2-carcinoma, a tumour capable of causing extensive fat depletion in the host (Costa & Holland, 1962) . Several lipolytic factors have been purified or partially purified from tumour cells. Thus a 75,000 Dalton protein, toxohormone L, has been isolated from tumour extracts and body fluids of patients and and animals (Masuno et al., 1981) , which, when injected into animals was capable of causing lipid mobilisation, immunosuppression and involution of the thymus gland (Masuno et al., 1984 ). An enhanced lipid mobilisation was also produced by serum of mice bearing a thymic lymphoma (Kitada et al., 1980) . Serum from a patient with advanced cancer also produced a similar effect (Kitada et al., 1981) . Initial studies on this factor indicated a molecular weight of about 5,000 Daltons, while later studies showed that the low molecular weight form was inactive, but aggregated on standing in the cold to become active (Kitada et al., 1982) . Recently we have demonstrated a lipid mobilising factor in extracts of the MAC16 colon adenocarcinoma, a tumour capable of producing a 30% loss of host body weight with a tumour burden of only 3%, and without a drop in caloric intake (Beck & Tisdale, 1987) . This material was also present in the serum suggesting a peripheral effect of the tumour. Lipid mobilising factors similar in charge and molecular weight to that found in the MAC16 tumour have recently also been identified in the serum of cachectic cancer patients.
These results suggest a generality of lipolytic factors in experimental cancer, but few studies have been carried out in patients. Production of lipolytic factors may be useful in the initial diagnosis of cancer patients and in determining the subsequent response to therapy. The level of such factors in body fluids of patients with various degrees of weight loss, with and without accompanying anorexia has been determined in the present study. As a control group we have used patients with senile dementia of the Alzheimer type in which patients may lose a considerable amount of weight with an apparently normal food intake (Sing et al., 1988) .
Materials and methods

Subjects
Twenty-four patients, 14 male and ten female with histologically proven malignancy and varying degrees of weight loss were entered into the study (Table I) . None of the patients were receiving therapy at the time of serum and urine collection. Weight loss was calculated from the premorbid weight. Appetite and food intake scores were documented by the patients using a simple questionnaire and linear analogue scale. In addition, 19 patients with senile dementia of the Alzheimer type, ten with weight loss and nine without, were also entered into the study (Table I) . The appetite and food intake of these patients was judged clinically. Seven normal laboratory workers served as diseasefree controls. Blood samples were allowed to clot on ice for 60 min, centrifuged and the serum separated and divided into five aliquots. Samples were stored at -70°C until assay. 
measure any spontaneous glycerol release. When assaying serum samples, a control (no adipocytes) was also included to measure the initial amount of glycerol present in the serum. Routinely samples of serum and urine (100 gl) were assayed in duplicate and the assay was repeated four to five times on each sample at different times using the separately stored aliquots. At the end of the incubation period, 0.5 ml of the incubation buffer was added to 0.5 ml of 10% (w/v) perchloric acid and the mixture was shaken to ensure deproteinisation. The precipitated protein was sedimented by centrifugation at 2,000 r.p.m. for 10 min, the supernatant removed and neutralised with 20% (w/v) KOH, after which the potassium perchlorate was sedimented by centrifugation (2,000 r.p.m., 10 min) and the volume of the supernatant was recorded and used to calculate the dilution factor. Assays on the supernatant were performed either immediately, or after storage at -20°C for between 18 and 72 h. The concentration of glycerol was determined enzymatically on 200 il aliquots of the supernatant by the method of Wieland (1974 
Results
The characteristics of the patients in this study are shown in Table I . Total percentage body weight loss varied between 0 and 50% and the rate of weight loss varied between 0 and 4.6 kg per week. The average weight loss in the cancer patient group (13.5 ± 2.9 kg) was not significantly different from that in the Alzheimer's group (14.0 ± 3.0 kg). Of the 21 evaluable cancer patients with weight loss, 16 (76%) reported a decrease in appetite and 15 (71%) reported a decreased food intake. Of these 15 only five (36%) reported a much greater decreased food intake than normal. All of the patients with cancer, but with no weight loss, had normal appetite and food intake scores. In general cancer patients who reported a normal food intake had a lower rate of weight loss (range 0-0.9 kg per week) compared with 10-12 10-11 10-1o 10-9 10-8 10-7 10-6 10-5 10-4
Log isoprenaline concentration (M) Figure 1 Dose-response relationship for the ability of isoprenaline to stimulate lipolysis, as measured by release of FFA, from murine epididymal adipocytes. The concentration of FFA in cell-free supernatants was determined immediately after incubation using a Wako NEFA C kit (Alpha Laboraties Ltd., Hampshire, UK) as previously described (Beck & Tisdale, 1987) .
patients with a reduced intake score (range 0.17-2.7 kg per week). Both the appetite and intake scores were irrespective of tumour type.
Serum lipolytic activity
The rate of glycerol release from murine adipocytes in response to both serum and urine samples increased linearly over a 3 h period, but tended to decrease with increasing time of incubation, and for this reason 2 h was chosen as a convenient incubation perioid for all samples. At the 2 h time point there was a doubling in the amount of glycerol released when the sample volume was increased from 50 to 100 jl4, but the linearity did not extend above this range. For this reason, and to obtain a larger change in absorbence value, the sample volume was restricted to 100 gl for both urine and serum. The serum and urine glycerol content was subtracted from the final figures. In the case of urine samples this value tended to be zero. The validity of the assay was established using isoprenaline as a positive control (Figure 1) .
The serum lipid mobilising activity of patients with cancer, Alzheimer's disease and normal healthy controls is given in adipocytes' ml-' serum) was not significantly different from the group without weight loss (0.11 ± 0.02 ytmol glycerol I05 adipocytes-'ml serum) or from the healthy control group (0.07 ± 0.02 jmol glycerol I05 adipocytes'ml-' serum), but all three groups were significantly lower (P <0.005) than the cancer patient group (0.20 ± 0.03 ytmol glycerol 105 adipocytes-' ml-' serum) irrespective of whether weight loss was apparent. Patients with cancer, but with no weight loss also had a significantly higher serum lipolytic activity (0.17 ± 0.03 jtmol glycerol I05 adipocytes-' ml-' serum) than the Alzheimer's group or healthy controls (P <0.001).
To try to understand variations in serum lipolytic activity with weight loss, measurements have been made in animals bearing the MAC16 adenocarcinoma, an experimental model of cachexia. Animals transplanted with this tumour are a heterogeneous group with weight loss appearing at various times after tumour transplantation. Occasionally animals bearing this tumour do not develop weight loss, although the growth of the tumour is similar to those in which weight loss is apparent. The results in Figure 2a show that for animals in which weight loss occurs there is a rise in the plasma level of lipolytic activity, which reaches a maximum when the animal has lost 16% of the body weight ( Figure 2b ) and thereafter decreases. Values of plasma lipolytic activity at all time points from day 4 to day 7 are significantly (P <0.01) higher than non-tumour-bearing controls. For animals without weight loss there is no significant elevation in plasma lipolytic activity above the value found in non tumour-bearing controls (Figure 2c ). This suggests a direct correlation between the rise in plasma lipolytic activity and the weight loss, although the relationship is only linear for the initial weight loss.
A similar relationship between serum lipolytic activity and weight loss was observed with the cancer patient group. Here there was a linear relationship between serum lipolytic activity and weight loss (correlation coefficient 0.79, n = 18) only when the total loss of body weight did not exceed 20% and weight loss was progressive (Figure 3) . Patients with higher percentage loss of body weight tended to have low levels of serum lipolytic activity, and these patients all reported a decrease in food intake, while a number of patients with lower weight loss reported a normal food intake. When only these subjects were included, the correlation between serum lipolytic activity and weight loss improved slightly (r = 0.84, n = 12) (Figure 4) .
Patients with previous weight loss who were stable during the study period had low levels of serum lipolytic activity (patients two and 19 with values of 0.09 ± 0.01 and 0.10 ± 0.003 imol glycerol released 105 adipocytes-' ml-' serum respectively) that was not elevated significantly above the controls.
Urine lipolytic activity In general the values for the urine lipolytic activity were qualitatively in line with the serum values (Table II) . However, the accuracy of detection was determined by the total volume of urine excreted since too dilute samples were below the limits of glycerol measurement. To counteract differences in urine volumes the urinary lipolytic activity has been expressed relative to the creatinine concentration of urine. The urine lipolytic activity for all cancer patients (0.67 ± 0.03 tmol glycerol released 105 adipocytes' mg creatinine'1 urine) was significantly elevated above normal (0) (Fair, 1973) . Anorexia is commonly reported in cancer patients (Bernstein, 1986) and in our study a high percentage (70%) of the weight losing cancer patients, reported a decrease in appetite polytic activity and and food intake. This was, however, only a subjective assesse lipolytic activity is ment by the patients and anorexia is sometimes denied by the adipocytes in a 2 h patient even though it may be present (Wesdorp et al., 1986) .
However, detailed studies have shown that the energy intake in ten cancer patients, who were below normal body weight and body cell mass, did not differ significantly from that of nine non-neoplastic control subjects, with diseases affecting physical activity to about the same extent (Warnold, et al may be important in cancer patients for providing increased lipid mobilisation under conditions where it might not be expected to occur, e.g. when the energy intake is normal. It is also known that a number of tumours have a limited ability to synthesise fatty acids and obtain a substantial amount preformed from the host (Spector & Bums, 1987) . Such fatty acids after only minor structural modification are incorporated into all of the complex lipids formed by the tumour cells, including the phospholipids needed for membrane synthesis and the formation of important regulatory metabolites such as eicosanoids and diacylglycerol. Thus the elaboration of a lipolytic factor may be essential for the growth and reproduction of neoplastic cells. However, measurement of the rate of whole body lipolysis in man using the glycerol turnover rate has shown no difference between cancer patients and controls (Jeevanandam et al., 1986) , although another study using the same technique reported an elevated glycerol turnover in progressive cancer (Eden et al., 1985) . Thus, whether the loss of body fat in patients with cancer cachexia is due to a reduced rate of lipogenesis or an augmented lipolysis still remains controversial, although our results would support the latter hypothesis.
The only urinary lipolytic factor so far described in humans was obtained from fasting subjects with intact pituitaries (Kekwick & Pawan, 1967) and has many of the characteristics of a cachectic factor. Thus when injected into mice this material mobilises body fat, increases the total metabolic turnover and causes weight loss without depressing appetite (Chalmers et al., 1958) . Another postulated cachectic factor, tumour necrosis factor/chachectin (TNF) produced by activated macrophages, may be correlated with appetite suppression and anorexia, but has no direct lipolytic activity in an in vitro assay (Mahony et al., 1988) . Furthermore, using a sensitive radioimmunoassay TNF was not detectable in the serum of patients with clinical cancer cachexia (Socher et al., 1988) . For this reason no estimation of the levels of TNF has been made in the present study.
The nature of the serum and urinary lipolytic factor found in the present study awaits its purification although preliminary results suggest that the material differs from the lipolytic hormones found in normal serum and is similar to the lipid mobilising factor elaborated by the cachexiainducing MAC16 adenocarcinoma in both charge and molecular weight. However, the elevated levels found in cancer patients may be a useful aid in the initial diagnosis of the disease and further studies will determine the response to therapy.
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